Amgen's anakinra slows joint damage in RA patients

AMGN announced additional data from a Phase II 472-patient trial of anakinra, an interleukin-1 receptor antagonist

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE